Migraine Med Shows Weight-Loss Benefit
Atogepant, an FDA-approved migraine medication, has shown potential for significant weight loss in patients with obesity. In a study, nearly one-third of participants experienced a weight reduction of 5% or more after one year of consistent use. Experts caution that while the findings are promising, further research is needed to confirm the weight loss effects across similar medications.
- ▪Atogepant is an oral CGRP receptor antagonist approved for migraine prevention.
- ▪In a study, 34.9% of participants achieved at least 5% weight reduction after one year.
- ▪The study involved 279 adults with episodic and chronic migraine and a BMI ≥ 25.
Opening excerpt (first ~120 words) tap to expand
CHICAGO — Atogepant (Qulipta, AbbVie), an oral, calcitonin gene-related peptide (CGRP) receptor antagonist FDA-approved for the prevention of migraine, may do more than reduce headache frequency — it may also drive meaningful weight loss in patients with overweight or obesity.In an open-label extension study, nearly one third of patients consistently taking atogepant 60 mg once daily experienced a 5% or greater weight reduction over 1 year of treatment, with about 13% having 10% or greater weight loss.For weight loss, patients “must take the 60 mg dose and they must take it consistently over time,” said Jessica Ailani, MD, director of the Medstar Georgetown Headache Center, Washington, DC.The study was presented on April 21 at the American Academy of Neurology (AAN) 2026 Annual…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
